ArticleScientific reports2025
Exploring natural AMPK activators from bioactive compounds in fenugreek and oyster mushroom for management of type 2 diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global trends, translational gaps, and emerging research directions inFrontiers in fungal biology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral antidiabetic drugs mainly act by stimulating pancreatic β-cells, but prolonged stimulation may lead to exhaustion and impaired insulin secretion. In contrast, AMP-activated protein kinase (AMPK) lowers blood glucose through an insulin-independent pathway, offering therapeutic potential. This study aims to identify AMPK activators in oyster mushrooms and fenugreek using GC-MS and bioinformatics analysis. The bioactive compounds in both samples were identified through GC-MS analysis. Molecular docking, pharmacokinetics, drug-likeness, toxicity, and molecular dynamics simulation (MDS) were employed to evaluate the therapeutic potential of the identified phytochemicals. The results showed that the ester class of compounds was the most abundant in both fenugreek and oyster mushroom extracts, identified by GC-MS analysis. Molecular docking revealed that the selected ligands exhibited strong binding affinities to the AMPK target protein. Pharmacokinetic and drug-likeness analyses confirmed that most compounds met acceptable ranges for potential AMPK activators. Molecular dynamics simulations further demonstrated that the selected ligands formed more stable ligand-protein complexes with fewer fluctuations compared to the control drug, glibenclamide. Overall, this study suggests that 2',6'-Dihydroxyacetophenone, 1-Methyl-2-phenylbenzimidazole, and N-Methylphthalimide are potential AMPK direct activators capable of mitigating Type 2 diabetes through an insulin-independent pathway. However, further in vitro and in vivo validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.